BriaCell Therapeutics Corp. (BCTX)

Market Cap	27.19M +128.5%
Revenue (ttm)	n/a
Net Income	-28.71M
EPS	-33.79
Shares Out	1.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	151,207
Open	3.730
Previous Close	3.760
Day's Range	3.600 - 3.850
52-Week Range	3.600 - 98.200
Beta	2.03
Analysts	Strong Buy
Price Target	40.00 (+989.92%)
Earnings Date	Mar 13, 2026

About BCTX

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: BCTX
• Website: https://briacell.com

Analyst Summary

According to one analyst, the rating for BCTX stock is "Strong Buy" and the 12-month stock price target is $40.0.

Price Target

$40.0

(989.92% upside)

Analyst Consensus: Strong Buy